Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.
about
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis opticaUpdated consensus statement on the use of rituximab in patients with rheumatoid arthritis.Response to rituximab in patients with rheumatoid arthritis in different compartments of the immune system.Rituximab for Rheumatoid Arthritis.Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsCan Synovial Pathobiology Integrate with Current Clinical and Imaging Prediction Models to Achieve Personalized Health Care in Rheumatoid Arthritis?Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment.Human T-follicular helper and T-follicular regulatory cell maintenance is independent of germinal centersAlternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations.B-cell subsets in the joint compartments of seropositive and seronegative rheumatoid arthritis (RA) and No-RA arthritides express memory markers and ZAP70 and characterize the aggregate pattern irrespectively of the autoantibody status.Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis.Expansion of Activated Peripheral Blood Memory B Cells in Rheumatoid Arthritis, Impact of B Cell Depletion Therapy, and Biomarkers of Response.The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patientsAnti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.Internalization of rituximab and the efficiency of B Cell depletion in rheumatoid arthritis and systemic lupus erythematosusRituximab Downregulates Gene Expression Associated with Cell Proliferation, Survival, and Proteolysis in the Peripheral Blood from Rheumatoid Arthritis Patients: A Link between High Baseline Autophagy-Related ULK1 Expression and Improved Pain ControB lymphocyte-typing for prediction of clinical response to rituximab.Immune cell profiling to guide therapeutic decisions in rheumatic diseasesA combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study.Repeated decrease of CD4+ T-cell counts in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis.Rituximab for the treatment of rheumatoid arthritis: an update.Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis.B cells as therapeutic targets in SLE.B cells in the pathogenesis and treatment of rheumatoid arthritis.Targeting B cells for the treatment of SLE: the beginning of the end or the end of the beginning?Unresolved issues in biologic therapy for rheumatoid arthritis.Current and future treatment approaches for neuromyelitis optica.Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity.B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies.Preliminary analysis of mortality associated with rituximab use in autoimmune diseases.Emerging immunotherapies for rheumatoid arthritis.An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus.Cytokine-producing B cells: a translational view on their roles in human and mouse autoimmune diseases.Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.
P2860
Q26748601-9AF92C05-2DC6-47D1-A955-625F6CF053FAQ27691388-19DB8AD6-FDEB-4A87-8565-46FA95D7B979Q27692640-46244D5A-7E2D-4460-B455-2766C5849773Q28080246-312091F4-B4B3-47C6-AF9C-856C9DB3AC99Q28290930-402C2703-A815-405E-B379-1F46604DE0F9Q33627758-E4F444D9-7B23-490D-886B-ACF032601C39Q34056237-29FA409E-C90B-42D2-88CC-AA99D5AC14C4Q34117122-3D26AD2C-5323-40B1-A820-15FF9953FCCEQ34398374-17DFDC5B-311C-4206-B4AC-7FCA51024BE2Q34810094-128C5C7D-37CB-448D-A335-06F8882677E0Q35026464-6F2CC39D-7F4B-4351-9354-24964A243D9DQ35286950-BA3EBDDD-BEC2-4DDD-8AF1-3C16A5F993E8Q35569500-79D00DCB-D862-452C-BC1D-68862428377DQ35654669-0A4AF31B-50B1-4154-A299-C5C12D99DC3BQ36245889-908C3D27-2585-4EF4-B81E-2D9959967B63Q36484465-D60EFC25-979C-42E7-9A99-08B43FDF54EEQ36532571-844EFA90-9DB9-4AB0-90C9-E2794B61B244Q36556219-F3D10DA8-0F91-469C-B426-E1EEACAF0278Q36633292-E443D5CB-3981-4BBC-B0A7-9FC6EAD9DB92Q36982828-641B7A83-5C68-4C0F-B58B-AB29226785DCQ37203531-6C3BC125-988B-4A56-AC9F-F662BE59B197Q37377989-F4C90BD7-64BF-4964-962B-C4BA6A6E453AQ37388213-96780DD1-42E8-4573-9883-7B2BA19E6478Q37444678-53F32AFD-B6F2-477D-B2D7-BA753EEEDC31Q37552019-C8B49BCE-7D1C-4B8B-A2D3-D256FB71E85BQ37586921-6A2940C5-3B2C-47C7-B11A-E16435FB4F78Q37603296-525D6EB6-64EC-4FE1-A26B-C1665B27A387Q37678888-4B9B25B9-BE03-4786-A008-F4AE169F2833Q37814530-94313A49-9005-4552-9667-AD55A0415D70Q37851001-A14D63C9-B967-4F9C-A502-EF7929877D4BQ37892874-11A10AE9-4FB1-4F4A-B35A-3DADFD6FB180Q38071110-FF8F2B71-2FEE-4DF2-BCE1-68436044F7F4Q38097170-40A0E5CE-8179-4FC6-B544-093C420DE9C1Q38154934-D9CBD388-7DC6-46D6-9576-035E959A7728Q38188862-7A9967A9-1D8E-404C-95D0-71EF17BBE90DQ38546315-1C7FB0CA-564F-4E8B-B794-2D4288048E61Q38673420-5598794C-0325-41E6-BD18-7A74BAC2524EQ38690022-DD4617D6-373E-447B-A579-1C759CC3CAB6Q38690330-079F0A66-1D76-4757-BF32-8734CA1199A8Q38819214-344915C2-05BC-4930-8988-CE5A7D628D6F
P2860
Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en-gb
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@nl
type
label
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en-gb
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@nl
prefLabel
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en-gb
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@nl
P2093
P50
P356
P1476
Highly sensitive B cell analys ...... erapy in rheumatoid arthritis.
@en
P2093
Edward M Vital
Karen Henshaw
Shouvik Dass
P304
P356
10.1002/ART.23902
P577
2008-10-01T00:00:00Z
P5875
P6179
1002362166